Investors of Erasca, Inc. Have Chance to Lead Class Action Lawsuit Amid Major Losses

Investor Alert: Opportunity to Lead the Erasca Class Action

Erasca, Inc. (NASDAQ: ERAS) has recently come under scrutiny as Robbins Geller Rudman & Dowd LLP announces a class action lawsuit aimed at helping investors who suffered significant losses during the Class Period from January 14, 2025, to April 26, 2026. The firm is actively seeking lead plaintiffs to represent other investors in this case, with a deadline for applications set for August 10, 2026. This lawsuit has been filed in the Southern District of California under the caption "Cheng v. Erasca, Inc., No. 26-cv-03481".

The foundation of the lawsuit rests on allegations that Erasca, a clinical-stage oncology company specializing in precision therapies for RAS/MAPK pathway cancers, misled investors regarding its lead product, ERAS-0015. Specifically, it claims that the company and its executives made false statements and failed to disclose critical information about the risks associated with the product’s preclinical data. The filing points to concerns over patent violations and trade secret infringement related to the development of ERAS-0015.

The situation escalated dramatically when, on April 27, 2026, Erasca disclosed receipt of a legal letter from Revolution Medicines asserting patent infringement related to ERAS-0015. Following this revelation, Erasca’s stock plummeted nearly 11%, indicating a swift reaction from the market. Furthermore, after market close on that same date, Erasca released preliminary Phase I clinical trial data, which included the unfortunate news of a patient’s death after taking ERAS-0015. They also stated that the comparisons made between ERAS-0015 and other candidates were not based on head-to-head clinical trial results, leading to a substantial decline of more than 48% in stock price post-announcement.

The class action suit allows any investor who purchased shares of Erasca during the class period to apply to become a lead plaintiff. This role is crucial, as the lead plaintiff represents all class members and plays a vital part in directing the litigation process. Notably, one does not have to be the lead plaintiff to benefit from any potential recovery in this case; all eligible investors will have access to the recovery if the case is successful.

Robbins Geller, a premier law firm specializing in securities fraud and shareholder rights litigation, has an impressive track record, having recovered over $8.4 billion for investors in the past five years. The firm's efforts in similar class action cases position it as a formidable advocate for those who have suffered due to corporate misconduct.

For those affected by this recent downturn at Erasca, contacting Robbins Geller is straightforward via their website or through their dedicated lawyers, Ken Dolitsky and Michael Albert, who are available for inquiries. Interested parties can find more details about the claims and how to participate in the class action by visiting Robbins Geller’s website.

In summary, if you have experienced significant financial losses due to investments in Erasca, Inc., this is a critical moment to evaluate your options and potentially take action as part of the forthcoming class action lawsuit. With the implications of this case being far-reaching for investors, timely responses will be essential in pursuing justice and seeking financial recovery.